Purpose The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of Ra scans. PET/CT imaging using 18 F-fluoride was performed prior to the first treatment (baseline), and at week 6 immediately before the second treatment and at week 12 after baseline. Results Absorbed doses to metastatic bone lesions ranged from 0.6 Gy to 44.1 Gy. For individual patients, there was an average factor difference of 5.3 (range 2.5-11.0) between the maximum and minimum lesion dose. A relationship between lesion-absorbed doses and serial changes in 
Introduction
Prostate cancer is the most commonly diagnosed noncutaneous malignancy in men [1] . A significant number of patients will present with metastatic disease in the bones. Hormonal therapy is used as a first line treatment but, in many cases, the disease will eventually cease to respond to hormonal therapies.
In these circumstances, a range of palliative treatment options for bone metastases due to castration-resistant prostate cancer (CRPC) are available, including a number of beta particle-emitting radionuclides that are selectively taken up in areas of increased osteoblastic activity. Examples of such molecular radiotherapy treatments include 89 Sr-chloride, 153 Sm-EDTMP, 186 Re-HEDP and 188
Re-HEDP. Due to the range of the beta particles, potential irradiation of normal bone marrow is anticipated and haematological toxicity is the main side-effect of such treatments [2] .
Recently, treatment with 223 Ra-dichloride has become available [3] . 223 Ra is an alpha-emitting radionuclide with a half-life of 11.4 days which also demonstrates increased uptake in regions of high osteoblastic activity. The short range of the alpha particles emitted (< 80 μm) enables high absorbed doses to be delivered to skeletal metastases whilst limiting the absorption of radiation within the bone marrow [4, 5] .
The emissions from 223 Ra include photons at energies that allow gamma camera imaging [6, 7] . However, patients receiving 23 Ra-dichloride are typically injected with 55 kBq/ kg body mass resulting in limited count statistics in the images. As a result, tomographic imaging is impractical whilst 2D whole-body 223 Ra images are characterised by significant levels of Poisson noise which can limit the positive identification of lesions for analysis. Nonetheless, two recent studies have used 2D gamma camera imaging to determine 223 Ra absorbed doses according to the Medical Internal RadiationDose (MIRD) formalism, to measure biodistribution and to calculate normal organ dosimetry in patients treated with 223 Ra-dichloride [8, 9] . In addition, Carrasquillo et al. [10] used 2D gamma camera imaging to demonstrate early bone uptake of 223 Ra as well as small bowel excretion. 2D gamma camera images were also used by Pacilio et al. [11] to calculate the absorbed dose to bone metastases in patients receiving 223 Ra-dichloride therapy. Notably, this group reported a range of lesion absorbed doses with an order of magnitude difference between the lowest and highest values. Earlier studies of 223 Ra therapy have already demonstrated a relationship between the activity administered to a particular cohort of patients (e.g. 25 kBq/kg vs. 50 kBq/kg) and the average change in pain index or prostate specific antigen (PSA) level across those cohorts [12, 13] . However, to date, there has been no evidence of a relationship between the lesion absorbed dose and response to treatment with 223 Ra-dichloride. 18 F-fluoride localises to the inorganic part of the bone, particularly in areas of osteoblastic activity, and has been used extensively for PET imaging of metastatic bone disease. Several studies have demonstrated superior sensitivity and specificity of 18 F-fluoride imaging in comparison to conventional bone scintigraphy [14, 15] . Fluoride ions are incorporated into the hydroxyapatite crystal structure of the bone by substitution for hydroxyl (OH) ions. The relationship between osteoblastic and osteoclastic activity is believed to determine the amount of incorporation into the bone [16] , given by.
In common with 18 F-fluoride, 223 Ra localises to areas of osteoblastic activity and the hydroxyapatite crystal structure is also thought to be the target for 223 Ra ions [4] . These ions are taken up into bone by ionic exchange with the calcium ions [17] . Given the common hydroxyapatite target, it can be hypothesised that pre-treatment 18 F-fluoride PET imaging may provide theragnostic information regarding the response of lesions to treatment with 223 Ra dichloride. In this study, the cumulated activity, the effective half-life and the range of absorbed doses delivered to a number of lesions were determined. The relationship between 223 Ra absorbed doses and subsequent changes in 18 F-fluoride uptake in these lesions was also investigated. To our knowledge, such doseresponse data for 223 Ra-dichloride therapy has not previously been published. Furthermore, the potential for a single pretreatment assessment of 18 F-fluoride uptake to predict lesion response to 223 Ra-dichloride treatment and to provide the basis for a surrogate dose-response relationship was investigated. Tc-MDP bone scintigraphy no less than 6 weeks prior to treatment were included in this study. Of the six patients recruited, five also underwent 18 F-fluoride PET/CT imaging. Only these five patients were included in this post-hoc analysis.
Materials and methods
Patients were scheduled to receive 100 kBq/kg of 223 Radichloride intravenously at baseline (therapy 1) and after 6 weeks (therapy 2). Following a revision of the primary standard for radionuclide calibrators [18, 19] , it was retrospectively acknowledged that, in fact, patients received 110 kBq/kg. Ra organ dosimetry in these patients has previously been reported [8] . A description of the changes in 18 F-fluoride uptake, concluding that 18 F-fluoride could be used as a biomarker to monitor response to 223 Ra-dichloride, has also been previously reported [20] as were eligibility criteria [8, 20] . Approval for the study was obtained from the appropriate research ethics committees and the national Administration of Radioactive Substances Advisory Committee, and all patients provided written informed consent. Tc-MDP. Imaging was performed on a Forte gamma camera (Philips Medical Systems, Cleveland, OH, USA) using a low-energy, high-resolution collimator according to a protocol previously detailed. Wholebody views were acquired for approximately 20 min using a matrix size of 256 × 1024. Imaging was performed using an energy window set at 140 +/− 10% keV.
223

Ra imaging
Sets of whole-body 223 Ra images were acquired in conjunction with each 223 Ra-dichloride administration. Imaging was performed on a Forte gamma camera (Philips Medical Systems, Cleveland, OH, USA) using a medium-energy, general purpose collimator according to a protocol previously detailed [6] . Whole-body and spot views were acquired for approximately 30 min each using matrix sizes of 256 × 1024 and 256 × 256 pixels, respectively. Imaging was performed using an energy window set at 82 +/− 20% keV. The first scan was acquired within 0-4 h post-injection and subsequent scans were acquired at 24, 48, 96 and 144 h post-injection. All images were acquired post-void to reduce artefacts due to radioactivity in the bladder. The count rate for all measurements was sufficiently low (< 1 kcts/s over the entire spectrum counted by the camera) such that no correction was required for detector dead-time. Ra uptake were selected. For superscan patients (2/5), selected whole vertebrae were delineated as were the femoral heads. In one case, an increased area of uptake in the right tibia was also selected. The 99m Tc images were manually registered to the 223 Ra images using Hermes Hybrid Viewer (Hermes Medical, Sweden) to rigidly transform the images, thereby allowing transfer of the ROIs to the 223 Ra whole-body and static images. The ROIs were then expanded in order to reduce the effect of spill-out due to partial volume effects and to limit the impact of any misregistration. Similarly to the work of Pacilio et al. [11] , a background correction for lesion uptake was determined from a region placed adjacent to the lesion ROI using the technique described by Buijs et al. [21] whereby the background region was used to calculate an average background count per pixel. ROI delineation was performed by four observers comprising three experienced dosimetry physicists and one dualaccredited consultant radiologist/nuclear medicine physician. The same consultant radiologist confirmed that all selected lesions were metastatic in nature.
Activity quantification was performed on the patient images according to either the conjugate view method or the single view effective point source method [22] . The conjugate view method was applied to those lesions situated close to a point equidistant between the anterior and posterior patient surface at the level of the lesion. The single view method was used to quantify uptake in lesions close to either the anterior or posterior surface which were not visible on the opposite view. Image counts were converted to activity using measured sensitivity and attenuation correction factors for 223 Ra as previously detailed [6] . The depth of a lesion within a patient was measured on the CT scan associated with the baseline 18 F-fluoride PET scan. Metastatic bone lesion volumes were measured by applying a fuzzy locally adaptive bayesian (FLAB) segmentation algorithm, initially developed for accurate outlining of PET data for radiotherapy planning, to the corresponding lesion sites on the baseline 18 F-fluoride PET images. [23] . The decay constant λ associated with the effective half-life, t 1/2 eff and initial activity, A 0 , of 223 Ra in identified lesions was calculated by fitting a single exponential to the time-activity curve. The fit was constrained such that the effective half-life could not be greater than the physical half-life. Cumulated activity was calculated according to:
The total mean absorbed dose, D, to the target region included contributions from the decay of the daughter products of Tl). The absorbed doses delivered to metastatic lesions by each isotope were calculated using self-irradiation S-factors for unit density spheres [24] , scaled for an assumed bone density of 1.3 g ml −1 [25] . The absorbed dose is then given by
where S i is the self-irradiation S-factor for isotope i and spherical volume V s ; and V t is the lesion volume as determined by PET imaging. No radiation weighting factor was used to adjust the reported absorbed doses. It was assumed that the biodistribution of the daughter isotopes was the same as the 223 Ra parent isotope [26] . F-fluoride PET scans were assessed semi-quantitatively for evidence of response at the 6-and 12-week time points compared to the baseline pre-treatment scan. In the case of one patient, the third PET scan was rejected for analysis due to technical problems with the image acquisition. FLAB-derived outlines of the 29 lesions identified on 99m Tc-MDP imaging were produced using an IDL routine incorporated into a Symbia.Net workflow (Siemens Healthcare, Germany). These were used to measure the SUV mean as well as the volume of each lesion. SUV mean values were corrected for partial volume effects as a function of lesion volume (V t ) using the following expression for recovery coefficient (RC) as described by Kessler et al. [27] where σ is the standard deviation of a Gaussian function describing the point spread function, determined by fitting Eq. 4 to the measured recovery curve associated with an IEC NEMA image quality phantom filled with 18 F. For the PET imaging described in this study, a value of σ = 4.3 mm was used.
The patient body mass and lesion volumes were used to convert values of SUV mean to percentage injected activity (%IA).
Percentage changes in SUV mean relative to the baseline PET study were used to define the response to 223 Radichloride therapy on a lesion by lesion basis. Changes were measured at both 6 weeks and 12 weeks after baseline. Response to treatment after 6 weeks was plotted as a function of the 223 Ra absorbed dose due to the first therapy. Response to treatment after 12 weeks was plotted as a function of the total 223 Ra absorbed dose. The SUV mean at baseline was compared to the calculated absorbed dose due to 223 Ra uptake in lesions. In addition, response to treatment at 6 weeks and 12 weeks post- 
Uncertainty analysis
Data were analysed using Graphpad Prism software. The as u(A 0 ) and u(λ), the uncertainty in those estimates, and r(A 0 , λ) the covariance of A 0 and λ. The overall uncertainty in the cumulated activity was calculated according to Eq. 6 [28] . The fractional uncertainty in the cumulated activity was used as an estimate of the fractional uncertainty in the absorbed dose estimate.
The uncertainties associated with the 18 F-fluoride uptake measurements were derived from the results of Lin et al. [29] who reported a coefficient of variation of 6.6% for lesion SUV mean .
Statistical analysis
The distribution of absorbed doses and the log-transform of this distribution were tested for normality using the D'Agostino-Pearson criteria. The Kruskal-Wallis test and its associated p value were used to compare the dose distributions resulting from the measurements of different observers.
Spearman rank correlation coefficients and their associated p values were calculated between the %IA of Ra WB images. The dosimetry results for these lesions are summarised in Table 1 . Absorbed doses ranged from 0.6 ± 0.3 Gy to 44.1 ± 16.4 Gy with a median absorbed dose of 4.1 Gy (see Fig. 2 ). There was no significant difference in the observed absorbed doses determined from the lesion outlines of each operator (p = 0.58). The log-transform of each distribution was found to be normally distributed. The median uncertainty in the lesion dose calculations (±1.0 Gy) was more than an order of magnitude less than the range of the calculated values. Approximately 80% of the absorbed dose in each lesion was due to alpha and beta particles emitted from the daughter isotopes. A full breakdown of the relative contribution of each isotope is given in Table 2 . The effective half-life of 223 Ra in lesions ranged from 44 h to 274 h (the physical half-life) with a median effective half-life of 136 h (See Fig. 3) .
A significant high correlation was observed between lesion uptake (A 0 ) at the time of the first therapy and the time of the Ra measured at the two different time points was also significantly correlated (r = 0.77, p < 0.0001) as was the relationship between the lesion absorbed doses (r = 0.85, p < 0.0001). These relationships are shown in Fig. 4 . 
Discussion
Absorbed doses in metastatic bone lesions ranged from 0.6 Gy to 44.1 Gy in this study. In other words, there is significant heterogeneity of absorbed dose across the patient population. For individual patients, there was an average factor difference of 5.3 (range 2.5-11.0) between the maximum and minimum lesion dose. Emissions from the daughter isotopes of 223 Ra contributed from 79-84% of this absorbed dose. The absorbed doses from 223 Ra emissions only were 0.1-9.4 Gy which encompass the range observed in the study by Pacilio et al. [11] . For deterministic cell-killing effects using alpha emitters, a factor of 5 for relative biological effectiveness (RBE) has been suggested [31, 32] . However, this has not been validated in human studies and, therefore, no corrections for RBE were made to the dosimetry data presented in this study.
The limited count statistics associated with 223 Ra wholebody imaging lead to uncertainties in the fitting of the timeactivity curves which in turn leads to the propagation of further uncertainty in the estimation of the absorbed dose. In this study, the uncertainty associated with the absorbed dose estimates ranged from 0.03 Gy to 16.4 Gy. Nevertheless, the median uncertainty in the lesion dose calculations (±1.0 Gy) was an order of magnitude less than the range of the calculated values, and inter-observer variation was not significant. No correlation was observed between uncertainty and lesion volume, nor between lesion absorbed dose and lesion volume. One way of reducing the uncertainty associated with these absorbed dose estimates could be to change the time points at which 223 Ra images are acquired. In our study, the latest imaging time points were at 6 days after administration. Pacilio et al. [11] imaged patients up to 24 days after administration, approximately 4 times the median effective half-life observed in our cohort and more in alignment with the MIRD recommendations for appropriate temporal sampling [22] .
A further source of uncertainty associated with molecular radiotherapy dosimetry is the estimation of lesion volume. In this study, the FLAB segmentation technique was used to measure volume. This technique developed for radiotherapy outlining has been shown to be both accurate and reproducible [33] . The use of this particular algorithm reduces interoperator variability in measurements of lesion volume to approximately 1% compared to~15% for manual delineation [34] . In the example image shown in Fig. 1 , the PET-derived outline of a rib lesion is seen to closely match the bony anatomy of the lesion demonstrated by the CT imaging. However, the use of a macroscopic volume is likely to give rise to a systematic error in the dose estimation since the true target volume, the endosteal layer, is an unknown fraction of the outlined volume.
Despite these uncertainties, a relationship between the absorbed dose to a lesion delivered over two cycles of therapy and the subsequent response as measured by suggested that the flare phenomenon, whereby an increase in 18 F-fluoride uptake is observed following treatment, may be partly responsible for this [35] .
The hypothesised relationship between 18 Tc-MDP uptake previously demonstrated by Pacilio et al. [11] . A strong correlation between 18 F-fluoride uptake and 223 Ra absorbed dose was also observed, despite a wide range in the Ra absorbed dose from low count planar data. Second, the measurement of mean SUV within a lesion is an analysis technique more commonly used in routine clinical practice than the analysis of serial whole-body images to calculate absorbed doses, although such dosimetry methodology is well established. Finally, the advantage of a surrogate measure for absorbed dose derived from a pretreatment 18 F-fluoride PET scan is that it represents prospective theragnostic information that could enable personalised treatment planning.
Earlier studies of 223 Ra therapy have already demonstrated a relationship between the activity administered to a particular cohort of patients (e.g. 25 kBq/kg vs. 50 kBq/kg) and the average change in pain index or PSA level across those cohorts [12, 13] . The wide range in the absorbed dose across multiple metastatic sites, along with the ability to image that dose distribution, either directly or through surrogate This study is limited by the number of patients recruited to the trial. In particular, the upper end of the dose-response curves could be better defined by additional data points. Nonetheless, if the relationship between initial 18 F-fluoride and the subsequent response to therapy observed in this investigation can be replicated in a larger patient cohort, Therefore, future trials would need to address several issues. Whilst this study suggests that the individual lesion absorbed doses are predictive of subsequent changes observed with functional imaging, the relationship between absorbed dose and other clinically relevant endpoints including pain index, changes in alkaline phosphatase (ALP) or PSA levels or prolonged survival should be investigated and quantified. This would further support the previous analysis of these patients by Cook et al. [20] that described a qualitative association between changes in the average SUVmax of selected lesions and changes in ALP and PSA.
In this study, a relationship between 18 F-fluoride uptake, 223 Ra absorbed dose and lesion response was demonstrated for two treatments of 110 kBq/kg. Further studies are required to investigate these results for alternative administration schedules, including the current standard regimen of 6 × 55 kBq/kg. The relationship between baseline uptake of 18 F-fluoride and response to two treatments of 100 kBq/kg demonstrated that non-responding lesions could be identified prior to therapy. This leads to the hypothesis that a subset of patients who would benefit from increased activities of 223 Ra-dichloride could be identified. Again, a suitably designed clinical trial would be required to test this hypothesis.
Conclusion
223
Ra lesion dosimetry performed using planar WB and static images of 223 Ra distribution show a wide range of absorbed doses across multiple sites of metastases. Evidence of a relationship between the 223 Ra absorbed dose to a lesion and the subsequent response defined by serial 18 F-fluoride imaging was observed.
A relationship was also observed between the 18 F-fluoride uptake prior to 223 Ra-dichloride treatment and the subsequent lesion response, indicating that 18 F-fluoride SUV mean could potentially act as a predictor of lesion absorbed dose. This is likely due to the fact that uptake of 18 F-fluoride in bone metastases is significantly correlated with both the corresponding uptake of 223 Ra and the associated 223 Ra absorbed dose. Larger trials are required to confirm these initial findings as well as to explore potential methodologies for optimising treatment.
